Fate Therapeutics announced its Q3 2026 financial results, highlighting progress in its off-the-shelf CAR T-cell therapies for lupus nephritis and autoimmune diseases. The company presented promising Phase 1 data supporting its Phase 2 RECLAIM-LN trial for lupus nephritis and initiated a Phase 1/2 trial for FT839, a dual-targeting CAR T-cell therapy. It secured a $15 million grant from CIRM and ended the quarter with $139.1 million in cash, extending its cash runway to mid-2028. Fate remains focused on clinical milestones and expanding its autoimmune and oncology pipeline through 2027.
Fate Therapeutics' Q3 2026 results provide context for health sector investors. For readers following health stocks, here is Pluang's market snapshot as of Nov 05, 2026 19:01 WIB: Among 150 priced health-sector US stocks, 94 rose and 48 fell. Notable movers include Edwards Lifesciences Corporation (EW) at USD 102.74 with a 3.39% increase and 85% sell order activity, LifeStance Health Group Inc. (LFST) at USD 14.67 with a 3.24% rise, and Cigna Corp (CI) at USD 315.00 with a 3.14% gain and 100% buy order activity, with typical hold times ranging from 0 to 67 days on Pluang.
Global tech giants like Amazon, Google, and Microsoft are committing hundreds of billions of dollars to expand AI-focused data center accelerators, driven by surging demand from generative AI workloads that exceed traditional CPU capabilities. These ...
Berkshire Hathaway's stock portfolio is now worth about three times what the company originally paid for it. These gains alone represent roughly 19% of Berkshire Hathaway's total company value, highlighting the significant growth and value generated ...
C3is Inc. will implement a one-for-five reverse stock split effective November 9, 2026, reducing its outstanding shares from about 4.2 million to 0.84 million. This move aims to increase the stock price to meet Nasdaq's minimum bid price requirement ...
Firmly secured $15 million in a Series A funding round led by Squarepoint Capital, with participation from J.P. Morgan Payments, Mastercard, and Samsung NEXT. The company provides a no-code platform that connects merchants to AI-driven shopping chann...
On November 4, 2026, Shell plc repurchased a total of 1,876,276 shares across multiple trading venues including LSE, Chi-X, BATS, XAMS, CBOE, and TQEX. The shares were bought at prices ranging from £37.98 to £38.82 and €45.70 to €46.72, with an avera...
